mapping the effectiveness and risks of glp 1 GLP-1 receptor agonists Mapping the effectiveness and risks
Description
Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people ...
Data on body weight and relevant clinical parameters were collected before and after 6 months of treatment with GLP1-RA
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus
It presents clinical strategies for adverse event mitigation, monitoring recommendations, contraindications, and practical considerations for treatment discontinuation or switching
pharmaceutical market grew 8.8% in 2024, to $348 bn
